Delivery |, targeting PD-1 and LAG-3 at the same time, double specific new drugs enter the clinical

Source: Wuxi apptec announced the clinical development progress of two new drugs developed by macrogenics on September 11, 2017 Mgd013, a new drug, can target immune checkpoint PD-1 and LAG-3 at the same time At present, the first patient began to receive mgd013 treatment At the same time, macrogenomics has submitted an ind application for another new drug, mgd014, which can target HIV infected cells and T cells carrying CD3 antigen at the same time The unique Dart (dual affinity re targeting) platform of M agrogenics can generate macromolecules that combine the specificity and affinity of antibodies with two different targets at the same time The technology platform can produce biomolecules based on antibody structure and combined with two or more targets at the same time The company's technology platform for dart production can customize the valence and half-life of dart molecules Mgd013 can be combined with the immunocheckpoint molecules PD-1 and LAG-3 expressed on the surface of T lymphocytes at the same time Mgd013 has a long half-life in serum By blocking the immunosuppression of these two immune checkpoint molecules at the same time, it has the potential to treat a variety of different cancers Earlier this year macrogenomics filed an ind application for mgd013 with the FDA Mgd014 is a dart molecule that can target both envelope proteins of HIV infected cells and T lymphocytes expressing CD3 Macrogenetics developed the product in 2015 in cooperation with the National Institute of allergy and infectious diseases (NIAID) It is the first dart molecule that targets infectious factors to enter clinical trials Preclinical studies have shown that using dart molecules to target HIV infected cells and T cells at the same time can turn the immune system's T cells to kill HIV infected cells Mgd014 can be used alone or in combination with HIV latency reversion agents to remove HIV infected cells Recently, NIAID decided to fund macrogenomics to promote mgd014 in phase 1 clinical trials, as well as the development and testing of section 2 dart molecule for HIV "Macrogenomics is committed to continuously promoting the research and development of products in clinical drug pipeline With the new development of mgd013 and mgd014, we now have multiple dart molecules tested in clinical trials, which involve different treatment fields and diseases, "said Dr Scott Koenig, President and CEO of macrogenetics.